Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 4,620 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Stock Performance

Shares of CYRX stock traded down $0.32 during trading hours on Tuesday, reaching $6.17. The company had a trading volume of 728,831 shares, compared to its average volume of 534,310. The business has a fifty day moving average price of $6.98 and a 200-day moving average price of $7.43. Cryoport, Inc. has a one year low of $4.58 and a one year high of $20.11. The firm has a market cap of $307.94 million, a PE ratio of -1.83 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. Sell-side analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

CYRX has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim initiated coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Institutional Trading of Cryoport

A number of large investors have recently made changes to their positions in CYRX. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after acquiring an additional 2,120 shares during the period. Lazard Asset Management LLC bought a new stake in Cryoport during the fourth quarter valued at approximately $51,000. Avanza Fonder AB bought a new stake in Cryoport during the fourth quarter valued at approximately $64,000. Quarry LP bought a new stake in Cryoport during the fourth quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Cryoport during the third quarter valued at approximately $82,000. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.